Margaret H Baron, MD, PhD
img_Margaret H Baron
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Oncological Sciences
PROFESSOR | Cell, Developmental & Regenerative Biology
Research Topics
Cancer, Cellular Differentiation, Cytokines, Developmental Biology, Embryology, Endothelial Cells, Gene Regulation, Genetics, Growth Factors and Receptors, Hematopoiesis, Imaging, Knockout Mice, Microarray, Migration, Molecular Biology, Morphogenesis, Nucleus, Organogenesis, Protein Complexes, Regeneration, Signal Transduction, Stem Cells, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice, Transplantation, Vascular Development
Multi-Disciplinary Training Area
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]

Our lab is interested in molecular mechanisms of hematopoietic stem and progenitor cell fate specification and differentiation using mouse and human primary cell and ES cell models and animals.  We have a longstanding interest in developmental hematopoiesis in mammals.  One focus of the lab is to study signaling pathways in embryonic hematopoiesis and erythropoiesis (red blood cells) in the mouse.  A second focus is on definitive (adult type) hematopoietic and erythroid progenitor development (mouse fetal liver or bone marrow, human progenitors from peripheral blood or bone marrow).  We are developing a high throughput screen for regulators of erythroid progenitors as well as later stages of maturation, including enucleation, and are targeting specific ligand-activated transcription factor pathways for detailed analysis.  Experimental approaches include classical cell and molecular biology techniques, small interfering RNA viral technologies, RNA profiling and RNAseq, computational analyses, chromatin immunoprecipitation (ChIP), and genetic manipulation of mice.  This work has the potential to reveal new approaches for regulating erythropoiesis and to suggest options for the development of novel therapies to improve the body’s ability to rapidly replenish its red blood cells.  They may also lead to the discovery of new targets in progenitors that could be exploited to develop methods for more efficient production ex vivo of red blood cells for transfusion.


AB Summa cum laude, Harvard University

PhD, Massachusetts Institute of Technology

MD, Harvard Medical School (Harvard-M.I.T. Program in Health Sciences and Technology)

Residency, Internal Medicine, Massachusetts General Hospital

Postdoc, Harvard University



Executive Leadership in Academic Medicine (ELAM) program


Elected Member

Association of American Physicians (AAP)


Research Recognition Award

American Cancer Society


Irene and Dr. Arthur M. Fishberg Professor of Medicine

Mount Sinai School of Medicine


Elected Member

American Society for Clinical Investigation (ASCI)


Basil O'Connor Scholar Award

March of Dimes


Scholar Award

Lucille P. Markey Charitable Trust Scholar Award

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Baron has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.